Do easy inspiration with marked difficulty expelling air (expiratory flow limitation and air‑trapping) coincide with amyotrophic lateral sclerosis (ALS)?

Expiratory Flow Limitation and Air-Trapping in ALS

Yes, marked difficulty expelling air with easy inspiration is characteristic of amyotrophic lateral sclerosis (ALS), though the pattern differs from typical obstructive lung disease. In ALS, expiratory muscle weakness leads to prolonged expiratory rise time and reduced peak expiratory flow, while inspiratory dysfunction also develops as the disease progresses 1.

Respiratory Pattern in ALS

Expiratory Dysfunction

• Expiratory rise time is significantly prolonged in ALS patients compared to healthy individuals, reflecting weakness of abdominal and expiratory muscles 1.
• Peak expiratory flow time (PEFT) increases significantly and linearly with disease progression in ALS, representing a sensitive quantitative measure of declining respiratory muscle strength 2.
• PEFT increases at a faster rate than the decline in both FVC and peak expiratory flow rate (PEFR), making it a useful early marker 2.
• Expiratory muscle weakness results in inability to generate cough spikes (transient supramaximal flow during cough) when cough gastric pressure falls below 50 cm H₂O 3.

Inspiratory Dysfunction

• Inspiratory muscle weakness is actually the primary determinant of both ventilatory failure and respiratory symptoms in ALS, not expiratory weakness 3.
• The inability to quickly and forcefully inspire during the inspiratory phase of voluntary cough places patients at a mechanical disadvantage to generate subsequent high-velocity expiratory airflow 4.
• Peak inspiratory flow rate and duration, along with inspiratory pressure generation, are significant predictors of peak expiratory cough flow in ALS 4.

Key Distinguishing Features from COPD

Different Mechanism

• Unlike COPD where expiratory flow limitation results from airway collapse and air-trapping due to loss of elastic recoil, ALS involves neuromuscular weakness affecting both inspiratory and expiratory muscles 5, 3.
• Airway resistance is normal in uncomplicated ALS, distinguishing it from obstructive airway diseases 6.
• The pattern shows reduction in effort-dependent flows: maximum expiratory flow at large lung volumes and maximum inspiratory flow at all lung volumes 6.

Clinical Presentation

• In ALS, severe diaphragmatic dysfunction causes poor inspiratory strength leading to symptomatic respiratory fatigue, hypercapnia, and hypoxemia, often first detected during supine sleep 7.
• Any elevation of pCO₂ in neuromuscular disease may herald an impending crisis, unlike COPD where the degree of acidosis is more important than hypercapnia 5.
• Patients with ALS may present with advanced chronic hypercapnia without prior medical recognition of respiratory decline 5.

Monitoring and Assessment

Pulmonary Function Testing

• Spirometry should be performed every 3-6 months in ALS patients at risk of respiratory complications 8, 9.
• FVC decline is well-documented, but PEFT provides an additional sensitive measure that may begin to plateau with bulbar symptoms 2.
• The FEV₁/FVC ratio may appear supernormal when volume-corrected due to reduced lung volumes 6.

Cough Assessment

• Peak cough flow (PCF) should be monitored, with values <270 L/min in adults indicating compromised secretion clearance ability 10.
• Cough insufficiency in ALS manifests as prolonged, slow, weak cough effort that impedes secretion clearance 9.
• Abdominal muscle weakness, when substantial, results in inability to generate transient supramaximal flow during cough 3.

Clinical Implications

Respiratory Failure Risk

• Respiratory failure is the major cause of morbidity and mortality in ALS, characterized by reduced lung volumes and ineffective cough 11.
• Severe compromise of diaphragmatic function due to marked motor unit loss causes poor inspiratory strength, leading to symptomatic respiratory fatigue 7.
• Weakness of expiratory muscles leads to cough weakness and poor bronchial clearance, increasing risk of respiratory tract infections 7.

Management Considerations

• Noninvasive ventilation (NIV) should be considered when pulmonary function testing indicates clinical need, typically when FVC ≤50% of predicted 5, 8.
• Airway clearance strategies including mechanical insufflation-exsufflation should be initiated early in disease progression to control proximal airway secretions 9.
• Specialized physiotherapy is needed to aid sputum clearance in neuromuscular disease 5.